|
|
Volumn 3, Issue 6, 2006, Pages 294-295
|
|
Can advanced non-small-cell lung cancer be treated with weekly instead of 3-weekly docetaxel? Commentary
a
|
|
Author keywords
Docetaxel; Non small cell lung cancer; Schedule; Survival; Toxicity
|
|
Indexed keywords
DOCETAXEL;
EPIDERMAL GROWTH FACTOR RECEPTOR;
ERLOTINIB;
EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;
IFOSFAMIDE;
NAVELBINE;
PACLITAXEL;
PEMETREXED;
PROTEIN TYROSINE KINASE INHIBITOR;
ADVANCED CANCER;
ALOPECIA;
ANEMIA;
BONE MARROW SUPPRESSION;
CANCER CONTROL;
CANCER PALLIATIVE THERAPY;
CANCER RECURRENCE;
CANCER RELAPSE;
CANCER SURVIVAL;
CLINICAL TRIAL;
COMPARATIVE STUDY;
DIARRHEA;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG APPROVAL;
DRUG DOSE REGIMEN;
DRUG EFFICACY;
FEBRILE NEUTROPENIA;
FOLLOW UP;
HUMAN;
LEUKOPENIA;
LUNG NON SMALL CELL CANCER;
METASTASIS;
MUCOSA INFLAMMATION;
NEUTROPENIA;
OVERALL SURVIVAL;
PATIENT SELECTION;
PREDICTION;
PRIORITY JOURNAL;
QUALITY OF LIFE;
QUESTIONNAIRE;
RISK REDUCTION;
SHORT SURVEY;
SINGLE NUCLEOTIDE POLYMORPHISM;
STOMATITIS;
SURVIVAL RATE;
SURVIVAL TIME;
THROMBOCYTOPENIA;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
VITAMIN SUPPLEMENTATION;
|
|
EID: 33745046851
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc0510 Document Type: Short Survey |
|
Times cited : (4)
|
|
References (5)
|
